While previous studies have highlighted the significance of DDX3X in lung cancer progression [22], and small molecule inhibitors such as RK-33 have been developed for treating lung cancer [23], no clinical trials involving DDX3X inhibitors have been initiated thus far. Here, DDX3X is linked to lung carcinoma.